Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis

Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Guinan, Kimberly, Mathurin, Karine, Au, Yunghan, Schuh, Andre C., Bui, Cat N., Chai, Xinglei, Lachaine, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601219/
https://www.ncbi.nlm.nih.gov/pubmed/36290869
http://dx.doi.org/10.3390/curroncol29100592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601219/
https://www.ncbi.nlm.nih.gov/pubmed/36290869
http://dx.doi.org/10.3390/curroncol29100592

Ejemplares similares